What is CDXI stock price today?

CDXI (Cardax Inc) stock is trading at $0.00 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CDXI stock going up or down today?

CDXI stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CDXI stock now?

The decision to buy CDXI depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CDXI a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CDXI based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CDXI stock overvalued or undervalued?

Use our DCF valuation calculator to determine if CDXI is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is CDXI's P/E ratio?

P/E ratio data for CDXI will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is CDXI's market cap?

CDXI (Cardax Inc) has a market capitalization of $0.00 billion, making it a small-cap stock.

What is CDXI's price to book ratio?

Price-to-book ratio for CDXI is available on our dashboard along with other valuation metrics.

Does CDXI pay dividends?

CDXI does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CDXI's dividend yield?

CDXI does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CDXI stock a good long-term investment?

CDXI's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CDXI's revenue growth rate?

CDXI has shown revenue growth of -0.3% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for CDXI are available on our dashboard with complete income statement analysis.

What are the risks of investing in CDXI?

Key risks for CDXI include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CDXI compare to its competitors?

Compare CDXI to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CDXI's performance and positioning.

What is CDXI's stock price target for 2026?

Our AI model provides price targets for CDXI based on fundamental analysis: Bull case $0.00 (+30%), Base case $0.00 (+15%), Bear case $0.00 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CDXI?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CDXI. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CDXI's next earnings report?

CDXI reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CDXI - Cardax Inc

NYSE * Healthcare * Biotechnology

$0.00

+$0.00 (+0.00%)

About Cardax Inc

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

CDXI Key Statistics

Market Cap

$0.00M

EPS

$-0.65

Revenue Growth

-0.3%

Employees

How CDXI Compares to Peers

CDXI is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CDXI(This stock)	$80.00	N/A	-0%	0.0%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Cardax Inc Company Information

Headquarters: 2800 Woodlawn Drive, Honolulu, HI, United States, 96822, undefined
Website: www.cardaxpharma.com
Sector: Healthcare
Industry: Biotechnology

Data Updated: April 17, 2026 at 6:07 AM EDT

Ready to invest in CDXI?

Commission-free trading available. Affiliate links.

Upcoming Events for CDXI

Dashboard

Enter a ticker to analyze